OR WAIT null SECS
The company has invested in a new pharmaceutical chemistry and microbiology facility in Scotland.
Eurofins Scientific announced on March 20, 2017 that it will be establishing a new pharmaceutical chemistry and microbiology facility in Livingston, Scotland as part of a £4-million (approximately $4.9-million) investment. The announcement follows Eurofins’ acquisition of Exova’s pharmaceutical, food, and water testing business in the United Kingdom and Ireland in July 2016, and the subsequent purchase of ILS’s pharmaceutical business in October 2016.
The 5800m2 facility at Brucefield Industry Park will house Eurofins’ biopharmaceutical testing business in the UK. The first phase of the project will include the development of a 1400 m2 of lab space and creates the scope for significant expansion.
“From the new facility, Eurofins BioPharma Product Testing UK will provide a range of GMP pharmaceutical testing services, including, but not exclusively, method development and validation, finished product and raw material testing, elemental impurity testing, micro testing, and stability studies,” Alison Clayton, general manager at Eurofins BioPharma Product Testing said in a statement.
As part of the investment, Eurofins BioPharma Product Testing UK will be purchasing a new inductively coupled plasma mass spectrometry machine, enabling the company to meet growing demand for this service. Eurofins will also invest in more high-performance liquid chromatography equipment, increasing its capacity by 40%.
Source: Eurofins BioPharma Product Testing